Progressive improvement in short-, medium- and long-term graft survival in kidney transplantation patients in Ireland - a retrospective study.
kidney transplant
long-term
outcomes
Journal
Transplant international : official journal of the European Society for Organ Transplantation
ISSN: 1432-2277
Titre abrégé: Transpl Int
Pays: Switzerland
ID NLM: 8908516
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
20
10
2018
revised:
23
11
2018
accepted:
12
06
2019
pubmed:
19
6
2019
medline:
1
4
2020
entrez:
19
6
2019
Statut:
ppublish
Résumé
It is often quoted that while short-term graft survival in kidney transplantation has improved in recent years, it has not translated into a commensurate improvement in long-term graft survival. We considered whether this was true of the entire experience of the national kidney transplant program in Ireland. A retrospective analysis of the National Kidney Transplant Service (NKTS) database was undertaken to investigate patient and graft survival for all adult first deceased donor kidney transplant recipients in Ireland, 1971-2015. Three thousand two hundred and sixty recipients were included in this study. Kaplan-Meier methods were used to estimate survival at each time period post transplant for the various eras of transplantation. Uncensored graft survival has improved over the course of the program in Ireland at various time points despite risk factors for graft failure progressively increasing over successive eras. For example the graft survival at 15 years post transplant has increased from 10% in 1971-1975 to 45% by 1996-2000. Ireland has experienced a progressive improvement in long-term graft survival following kidney transplantation. Whether these trends are attributable to biological or nonbiological factors is unclear but likely involves a combination of both.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
974-984Informations de copyright
© 2019 Steunstichting ESOT.
Références
Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378.
Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011; 11: 450.
Keith DS, Vranic G, Nishio-Lucar A. Graft function and intermediate-term outcomes of kidney transplants improved in the last decade: analysis of the United States Kidney Transplant Database. Transplant Direct 2017; 3: e166.
Wang JH, Skeans MA, Israni AK. Current status of kidney transplant outcomes: dying to survive. Adv Chronic Kidney Dis 2016; 23: 281.
Gondos A, Dohler B, Brenner H, Opelz G. Kidney graft survival in Europe and the United States: strikingly different long-term outcomes. Transplantation 2013; 95: 267.
Traynor C, Jenkinson A, Williams Y, et al. Twenty-year survivors of kidney transplantation. Am J Transplant 2012; 12: 3289.
https://www.hse.ie/eng/staff/pcrs/about-pcrs/.
https://www.hse.ie/eng/services/list/1/schemes/drugspaymentscheme/.
Searles A, Doran E, Faunce TA, Henry D. The affordability of prescription medicines in Australia: are copayments and safety net thresholds too high? Aust Health Rev 2013; 37: 32.
Morgan S, Kennedy J. Prescription drug accessibility and affordability in the United States and abroad. Issue Brief (Commonw Fund) 2010; 89: 1.
Zaprutko T, Kopciuch D, Kus K, et al. Affordability of medicines in the European Union. PLoS ONE 2017; 12: e0172753.
Gordon EJ, Prohaska TR, Sehgal AR. The financial impact of immunosuppressant expenses on new kidney transplant recipients. Clin Transplant 2008; 22: 738.
James A, Mannon RB. The cost of transplant immunosuppressant therapy: Is this sustainable? Curr Transplant Rep 2015; 2: 113.
Muduma GTA, Dam S, Hawken N, Aballea S, Odeyemi I. Conference proceeding: International Society for Pharmacoeconomics and Outcomes “The Economic Burden after Renal Transplantation in Europe. Presented at the ISPOR 21st Annual International Meeting, 21-25 May 2016, Washington, DC, USA. 2016. Available at: https://wwwispororg/research_pdfs/52/pdffiles/PUK16pdf
National Renal Transplant Registry. Available at: https://wwwhiqaie/areas-we-work/health-information/data-collections/national-renal-transplant-registry.
Johnson C, Ahsan N, Gonwa T, et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 69: 834.
Margreiter R, European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359: 741.
Gonwa T, Johnson C, Ahsan N, et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation 2003; 75: 2048.
Ahsan N, Johnson C, Gonwa T, et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. Transplantation 2001; 72: 245.
Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997; 63: 39.
Miller J, Mendez R, Pirsch JD, Jensik SC. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. Transplantation 2000; 69: 875.
Bannon FJ, McCaughan JA, Traynor C, et al. Surveillance of nonmelanoma skin cancer incidence rates in kidney transplant recipients in Ireland. Transplantation 2014; 98: 646.
Collett D. Modelling Survival Data in Medical Research. London: Chapman & Hall, 1994: 116-119.
Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9(Suppl 3): S1.
Stegall MD, Gaston RS, Cosio FG, Matas A. Through a glass darkly: seeking clarity in preventing late kidney transplant failure. J Am Soc Nephrol 2015; 26: 20.
Gaston RS, Fieberg A, Hunsicker L, et al. Late graft failure after kidney transplantation as the consequence of late versus early events. Am J Transplant 2017.
Galichon P, Xu-Dubois YC, Finianos S, Hertig A, Rondeau E. Clinical and histological predictors of long-term kidney graft survival. Nephrol Dial Transplant 2013; 28: 1362.
Johnston O, O'Kelly P, Spencer S, et al. Reduced graft function (with or without dialysis) vs immediate graft function-a comparison of long-term renal allograft survival. Nephrol Dial Transplant 2006; 21: 2270.
http://www.anzdata.org.au/anzdata/AnzdataReport/40thReport/c07_transplant_2016_v1.0_20180509.pdf.
Coemans M, Susal C, Dohler B, et al. Analyses of the short- and long-term graft survival after kidney transplantation in Europe between 1986 and 2015. Kidney Int 2018.
Phelan PJ, O'Kelly P, Tarazi M, et al. Renal allograft loss in the first post-operative month: causes and consequences. Clin Transplant 2012; 26: 544.
Gaston RS. Improving long-term outcomes in kidney transplantation: towards a new paradigm of post-transplant care in the United States. Trans Am Clin Climatol Assoc 2016; 127: 350.
Merion RM, Goodrich NP, Johnson RJ, et al. Kidney transplant graft outcomes in 379 257 recipients on 3 continents. Am J Transplant 2018; 18: 1914.
USRDS Annual Data Report 2017. Available at: https://wwwusrdsorg/2017/download/v2_c06_Transplant_17pdf.
Hart A, Smith JM, Skeans MA, et al. OPTN/SRTR 2016 annual data report: kidney. Am J Transplant 2018; 18(Suppl 1): 18.
http://atcmeetingabstracts.com/abstract/comparison-of-20-year-patient-and-graft-survival-for-all-types-of-solid-organ-transplants-txs/.
European Renal Association Annual Report. https://wwwera-edta-regorg/files/annualreports/pdf/AnnRep2015pdf.
NHSBT Annual Report. https://www.odt.nhs.uk/statistics-and-reports/organ-specific-reports/.
Kerman RH, Kimball PM, Van Buren CT, Lewis RM, Kahan BD. Possible contribution of pretransplant immune responder status to renal allograft survival differences of black versus white recipients. Transplantation 1991; 51: 338.
Gordon EJ, Ladner DP, Caicedo JC, Franklin J. Disparities in kidney transplant outcomes: a review. Semin Nephrol 2010; 30: 81.
Tahir S, Gillott H, Jackson-Spence F, et al. Do outcomes after kidney transplantation differ for black patients in England versus New York State? A comparative, population-cohort analysis. BMJ Open 2017; 7: e014069.
Ward FL, O'Kelly P, Donohue F, et al. The influence of socioeconomic status on patient survival on chronic dialysis. Hemodial Int 2015; 19: 601.
Potter LM, Maldonado AQ, Lentine KL, et al. Transplant recipients are vulnerable to coverage denial under Medicare Part D. Am J Transplant 2018.
https://www.hse.ie/eng/.
Eckhoff DE, Young CJ, Gaston RS, et al. Racial disparities in renal allograft survival: a public health issue? J Am Coll Surg 2007; 204: 894; discussion -3.
Tanriover B, Stone PW, Mohan S, Cohen DJ, Gaston RS. Future of Medicare immunosuppressive drug coverage for kidney transplant recipients in the United States. Clin J Am Soc Nephrol 2013; 8: 1258.
Lefaucheur C, Loupy A, Zeevi A. Complement-binding anti-HLA antibodies and kidney transplantation. N Engl J Med 2014; 370: 85.
Pippias M, Stel VS, Areste-Fosalba N, et al. Long-term kidney transplant outcomes in primary glomerulonephritis: analysis from the ERA-EDTA registry. Transplantation 2016; 100: 1955.
Limaye S, O'Kelly P, Harmon G, et al. Improved graft survival in highly sensitized patients undergoing renal transplantation after the introduction of a clinically validated flow cytometry crossmatch. Transplantation 2009; 87: 1052.
Foster BJ, Mitsnefes MM, Dahhou M, Zhang X, Laskin BL. Changes in excess mortality from end stage renal disease in the United States from 1995 to 2013. Clin J Am Soc Nephrol 2018; 13: 91.
https://www.cso.ie/en/index.html.
Halloran PF, Famulski KS, Reeve J. Molecular assessment of disease states in kidney transplant biopsy samples. Nat Rev Nephrol 2016; 12: 534.